Pfizer vaccine ruling strengthens makers' immunity to lawsuits

Share this article:
The Supreme Court bolstered a law shielding vaccine makers from injury lawsuits.

Six of the court's justices ruled against a Pennsylvania family seeking to sue Pfizer for their daughter's seizure disorder, which they allege was caused by Wyeth predecessor Lederle Laboratories' diphtheria-tetanus-pertussis vaccine, which was discontinued in 1998. The court found that the National Childhood Vaccine Injury Act of 1986, which was designed to keep pharmas from bailing out of the vaccine market by creating a no-fault system of compensation for vaccine-related injury or death, prohibited such a suit. The parents' initial claims were denied by a Federal adjudicator under the 1986 Act. They then filed suit in Pennsylvania.

Writing for the majority, Justice Antonin Scalia said: “Provided that there was proper manufacture and warning, any remaining side effects, including those resulting from design defects, are deemed to have been unavoidable.”

Justices Sonia Sotomayor and Ruth Bader Ginsburg dissented, while Justice Elena Kagan recused herself.  In her dissent, Sotomayor said the decision ignores the intent of Congress and “leaves a regulatory vacuum in which no one ensures that vaccine manufacturers adequately take account of scientific and technological advancements when designing or distributing their products.”

Pfizer hailed the decision as “a win for public health.” EVP and general counsel Amy Schulman said in a statement: “The Vaccine Act that Congress enacted nearly 25 years ago appropriately places the responsibility for determining the optimal design of life-saving childhood vaccines in the hands of expert federal agencies, not a patchwork of state tort systems.”



 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...